{
  "id": "467325eebba89af7",
  "title": "CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID - 103 for Renal Allograft Antibody - Mediated Rejection ( AMR ) ",
  "description": "20260115T173000Z",
  "content": "",
  "source": "newjerseytelegraph.com",
  "source_url": "http://www.newjerseytelegraph.com/news/278811282/casi-pharmaceuticals-announces-approval-of-clinical-trial-application-by-china-nmpa-for-phase-1-2-study-of-cid-103-for-renal-allograft-antibody-mediated-rejection-amr",
  "published_at": "20260115T173000Z",
  "fetched_at": "2026-01-16T00:24:08.160649+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "china"
  ],
  "location": "United States",
  "raw_data": {
    "url": "http://www.newjerseytelegraph.com/news/278811282/casi-pharmaceuticals-announces-approval-of-clinical-trial-application-by-china-nmpa-for-phase-1-2-study-of-cid-103-for-renal-allograft-antibody-mediated-rejection-amr",
    "url_mobile": "",
    "title": "CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID - 103 for Renal Allograft Antibody - Mediated Rejection ( AMR ) ",
    "seendate": "20260115T173000Z",
    "socialimage": "",
    "domain": "newjerseytelegraph.com",
    "language": "English",
    "sourcecountry": "United States"
  }
}